Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Advances in cancer therapies including immunotherapy, chemotherapy, targeted agents, hormonal therapy, surgery, and radiation therapy have significantly improved cancer treatment and patient outcomes. However, these treatments can lead to a range of toxicities, which can significantly impact patients’ quality of life and long-term health. Understanding which patients are affected by treatment toxicity, and the reasons why, can help to inform strategies to manage adverse effects and develop novel therapies with reduced toxicities.
We invite submissions of primary research with a focus on minimizing and mitigating cancer therapy-related toxicity, and/or identifying new insights into the epidemiology and pathophysiology of both acute and late toxicities. We encourage submission of manuscripts describing the early detection, prediction, prevention, and patient-centered monitoring and management of cancer therapy-related toxicity. This includes studies evaluating the efficacy and safety of various interventions, such as supportive care measures, drug therapies, and lifestyle modifications, aimed at reducing toxicity and improving patient outcomes. We also welcome preclinical work that examines the mechanistic basis of cancer therapy-related toxicity, which may inform future mitigation approaches, or articles exploring the use of digital tools to minimize toxicity and improve management. Additionally, we are particularly eager to receive studies evaluating toxicities related to newer cancer therapeutic classes, such as cellular therapies. In addition to primary research, we welcome submissions of other article types, such as Reviews, Perspectives, and Comments that provide significant insights into the topic. All submissions will be subject to the same review process and editorial standards as regular Communications Medicine Articles.